16:38 EDT 4D Molecular (FDMT) sees cash, equivalents funding planned operations into 2028
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular announces RMAT designation granted by FDA for 4D-150 for DME
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- 4D Molecular price target lowered to $40 from $42 at BofA
- 4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial